EAM
SABSW icon

Exos Asset Management’s SAB Biotherapeutics Warrant SABSW Stock Holding History

Exos Asset Management’s Portfolio SABSW Stock Details SABSW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-27,500
Closed -$25K – 378
2021
Q3 		$25K Buy
27,500
+15,000
+120% +$10.7K 0.01% 358
2021
Q2 		$11K Hold
12,500
– – 0.01% 763
2021
Q1 		$8K Buy
+12,500
New +$13K 0.01% 392

Other funds holding SABSW

SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return
RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
YCM
Yakira Capital Management Westport, Connecticut $342M AUM 26.97% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
ICMH
Integrity Capital Management (HK) Central, Hong Kong $64K AUM
MS
Maven Securities St Helier, Jersey $5.2B AUM 44.01% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
EPM
Equitec Proprietary Markets Chicago, Illinois $559M AUM 230.29% 1-Year Est. Return

Exos Asset Management's SABSW Position: Q4 2021 in Review

Exos Asset Management sold out of SAB Biotherapeutics Warrant (SABSW) in Q4 2021, closing a stake of 27,500 shares — an estimated $25K sold.

Exos Asset Management first reported a position in SABSW in Q1 2021 and held it in 3 quarters. The position peaked at $25K in Q3 2021. 21 funds tracked by Wall St. Rank hold SABSW as of Q4 2021.

  • Exos Asset Management reported no remaining SAB Biotherapeutics Warrant position as of Q4 2021 after selling out during the quarter.
  • Exos Asset Management sold 27,500 SAB Biotherapeutics Warrant shares in Q4 2021, an estimated $25K.
  • Exos Asset Management first reported a position in SAB Biotherapeutics Warrant in Q1 2021 and held it in 3 quarters.
  • Exos Asset Management's SAB Biotherapeutics Warrant position peaked at $25K in Q3 2021.
  • 21 funds tracked by Wall St. Rank held SAB Biotherapeutics Warrant as of Q4 2021.

Based on Exos Asset Management's 13F filing for Q4 2021, filed 14 Mar 2022.